JP2010513435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513435A5 JP2010513435A5 JP2009542195A JP2009542195A JP2010513435A5 JP 2010513435 A5 JP2010513435 A5 JP 2010513435A5 JP 2009542195 A JP2009542195 A JP 2009542195A JP 2009542195 A JP2009542195 A JP 2009542195A JP 2010513435 A5 JP2010513435 A5 JP 2010513435A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- hydrogen
- ring
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- -1 -OR 9 Chemical group 0.000 claims 1
- FWFABQINPRGOOH-HMZWWLAASA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2H-tetrazol-5-ylmethyl)pyrazole-3-carboxylic acid (1R)-N-methyl-1-[4-(trifluoromethoxy)phenyl]ethanamine Chemical compound C[C@H](C(C=C1)=CC=C1OC(F)(F)F)NC.OC(C(C(CC1=NN=NN1)=C1C(C=C2)=CC=C2Cl)=NN1C(C=CC=C1)=C1Cl)=O FWFABQINPRGOOH-HMZWWLAASA-N 0.000 claims 1
- ZRXDEDIUKOZYJZ-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)-n-[(1r)-1-[3-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC1=NN=NN1 ZRXDEDIUKOZYJZ-OAHLLOKOSA-N 0.000 claims 1
- JKLSGJJVZPRNDK-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)-n-[(1r)-1-[4-(trifluoromethoxy)phenyl]ethyl]pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 JKLSGJJVZPRNDK-OAHLLOKOSA-N 0.000 claims 1
- DANBLBWVACCFGQ-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)-n-[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 DANBLBWVACCFGQ-OAHLLOKOSA-N 0.000 claims 1
- DISPWRFTNSDJNJ-CQSZACIVSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-n-[(1r)-1-(3,4-dichlorophenyl)ethyl]-4-(2h-tetrazol-5-ylmethyl)pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 DISPWRFTNSDJNJ-CQSZACIVSA-N 0.000 claims 1
- CZGTZPBJMUIHQR-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-n-[(1r)-1-(3-fluorophenyl)ethyl]-4-(2h-tetrazol-5-ylmethyl)pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(F)C=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC1=NN=NN1 CZGTZPBJMUIHQR-OAHLLOKOSA-N 0.000 claims 1
- LOVAGEWSHISHOL-OAHLLOKOSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]carbamoyl]pyrazol-4-yl]acetic acid Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=1CC(O)=O)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 LOVAGEWSHISHOL-OAHLLOKOSA-N 0.000 claims 1
- BUNZMHKUTFMZHO-MRXNPFEDSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[methyl-[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]carbamoyl]pyrazol-4-yl]acetic acid Chemical compound CN([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=1CC(O)=O)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 BUNZMHKUTFMZHO-MRXNPFEDSA-N 0.000 claims 1
- XIEINPMUURJODF-OAHLLOKOSA-N 2-[3-[[(1r)-1-(4-bromophenyl)ethyl]carbamoyl]-1-(2-chlorophenyl)-5-(4-chlorophenyl)pyrazol-4-yl]acetic acid Chemical compound N([C@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=1CC(O)=O)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 XIEINPMUURJODF-OAHLLOKOSA-N 0.000 claims 1
- IIXJQJVDFVHSCR-FCXZQVPUSA-N C[C@H](C(C=C1)=CC(Cl)=C1F)NC.OC(C(C(CC1=NN=NN1)=C1C(C=C2)=CC=C2Cl)=NN1C(C=CC=C1)=C1Cl)=O Chemical compound C[C@H](C(C=C1)=CC(Cl)=C1F)NC.OC(C(C(CC1=NN=NN1)=C1C(C=C2)=CC=C2Cl)=NN1C(C=CC=C1)=C1Cl)=O IIXJQJVDFVHSCR-FCXZQVPUSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- ZPKGALGAAPEZPS-OAHLLOKOSA-N N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 ZPKGALGAAPEZPS-OAHLLOKOSA-N 0.000 claims 1
- DCJYTZRLZIIFAO-OAHLLOKOSA-N N([C@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 Chemical compound N([C@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 DCJYTZRLZIIFAO-OAHLLOKOSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- QTJMKOMANNLMQO-CQSZACIVSA-N n-[(1r)-1-(4-chloro-3-fluorophenyl)ethyl]-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(F)C(Cl)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 QTJMKOMANNLMQO-CQSZACIVSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625197A GB0625197D0 (en) | 2006-12-18 | 2006-12-18 | Cannabinoid receptor modulators |
| GB0625197.9 | 2006-12-18 | ||
| GB0717998.9 | 2007-09-14 | ||
| GB0717998A GB0717998D0 (en) | 2007-09-14 | 2007-09-14 | Canabinoid receptor modulators |
| PCT/GB2007/004831 WO2008075012A1 (en) | 2006-12-18 | 2007-12-17 | Cb1 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513435A JP2010513435A (ja) | 2010-04-30 |
| JP2010513435A5 true JP2010513435A5 (enExample) | 2011-02-10 |
| JP5437812B2 JP5437812B2 (ja) | 2014-03-12 |
Family
ID=39156232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542195A Expired - Fee Related JP5437812B2 (ja) | 2006-12-18 | 2007-12-17 | Ｃｂ１受容体モジュレーター |
| JP2009542200A Expired - Fee Related JP5222855B2 (ja) | 2006-12-18 | 2007-12-17 | Ｃｂ１受容体のモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542200A Expired - Fee Related JP5222855B2 (ja) | 2006-12-18 | 2007-12-17 | Ｃｂ１受容体のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8148404B2 (enExample) |
| EP (2) | EP2121659B1 (enExample) |
| JP (2) | JP5437812B2 (enExample) |
| CN (1) | CN103145620A (enExample) |
| AU (2) | AU2007336061B2 (enExample) |
| BR (1) | BRPI0720732A2 (enExample) |
| CA (2) | CA2673177A1 (enExample) |
| EA (1) | EA017170B1 (enExample) |
| IL (2) | IL198989A0 (enExample) |
| MX (1) | MX2009006214A (enExample) |
| NZ (1) | NZ578063A (enExample) |
| WO (3) | WO2008075019A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7977358B2 (en) * | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| CA2708706A1 (en) * | 2007-12-10 | 2009-06-18 | 7Tm Pharma A/S | Cannabinoid receptor modulators |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| EP3028683B1 (en) | 2011-07-14 | 2018-05-09 | Cook Medical Technologies LLC | A kit to be used in the treatment of obstructive sleep apnea |
| US9710644B2 (en) | 2012-02-01 | 2017-07-18 | Servicenow, Inc. | Techniques for sharing network security event information |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| EP2908770B1 (en) | 2012-10-16 | 2019-04-24 | Cook Medical Technologies LLC | Apparatus for treating obstructive sleep apnea (osa) |
| EP3498239B1 (en) | 2013-08-01 | 2021-04-21 | Cook Medical Technologies LLC | Tissue adjustment implant |
| US10166017B2 (en) | 2013-08-05 | 2019-01-01 | Cook Medical Technologies Llc | Medical devices having a releasable tubular member and methods of using the same |
| US9956384B2 (en) | 2014-01-24 | 2018-05-01 | Cook Medical Technologies Llc | Articulating balloon catheter and method for using the same |
| US9974563B2 (en) | 2014-05-28 | 2018-05-22 | Cook Medical Technologies Llc | Medical devices having a releasable member and methods of using the same |
| WO2016022454A1 (en) | 2014-08-04 | 2016-02-11 | Darin Schaeffer | Medical devices having a releasable tubular member and methods of using the same |
| US11357660B2 (en) | 2017-06-29 | 2022-06-14 | Cook Medical Technologies, LLC | Implantable medical devices for tissue repositioning |
| EP3840854A4 (en) * | 2018-08-20 | 2022-06-29 | Bessor Pharma, LLC | Novel cannabinoids and cannabinoid acids and their derivatives |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| WO2026067383A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海轻胜谦远生物科技有限公司 | 咪唑并吡啶衍生物及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| CA2387892A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| PL208098B1 (pl) * | 2000-03-23 | 2011-03-31 | Solvay Pharm Bv | Pochodne 4,5-dihydro-1H-pirazolu, kompozycja farmaceutyczna, sposób wytwarzania związków oraz ich zastosowanie |
| CA2439152C (en) * | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| WO2004050632A1 (en) * | 2002-12-02 | 2004-06-17 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives useful as cox-i inhibitors |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| CA2524397A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
| US20090149463A1 (en) | 2004-02-20 | 2009-06-11 | Leifeng Cheng | Therapeutic agents |
| FR2867685B1 (fr) * | 2004-03-17 | 2008-05-23 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive |
| EP1831177A1 (en) | 2004-12-23 | 2007-09-12 | AstraZeneca AB | Therapeutic agents |
| WO2006133926A1 (en) * | 2005-06-17 | 2006-12-21 | Carex Sa | Pyrazole derivates as cannabinoid receptor modulators |
| AU2007226673A1 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
-
2007
- 2007-12-17 NZ NZ578063A patent/NZ578063A/en not_active IP Right Cessation
- 2007-12-17 EP EP07848579.4A patent/EP2121659B1/en not_active Not-in-force
- 2007-12-17 AU AU2007336061A patent/AU2007336061B2/en not_active Ceased
- 2007-12-17 AU AU2007336068A patent/AU2007336068B2/en not_active Ceased
- 2007-12-17 MX MX2009006214A patent/MX2009006214A/es active IP Right Grant
- 2007-12-17 EP EP07848570.3A patent/EP2121617B1/en not_active Not-in-force
- 2007-12-17 US US12/518,446 patent/US8148404B2/en not_active Expired - Fee Related
- 2007-12-17 CN CN2012103916453A patent/CN103145620A/zh active Pending
- 2007-12-17 JP JP2009542195A patent/JP5437812B2/ja not_active Expired - Fee Related
- 2007-12-17 CA CA002673177A patent/CA2673177A1/en not_active Abandoned
- 2007-12-17 BR BRPI0720732-8A patent/BRPI0720732A2/pt not_active IP Right Cessation
- 2007-12-17 CA CA002673359A patent/CA2673359A1/en not_active Abandoned
- 2007-12-17 WO PCT/GB2007/004842 patent/WO2008075019A1/en not_active Ceased
- 2007-12-17 JP JP2009542200A patent/JP5222855B2/ja not_active Expired - Fee Related
- 2007-12-17 WO PCT/GB2007/004835 patent/WO2008075013A1/en not_active Ceased
- 2007-12-17 US US12/519,432 patent/US8124634B2/en not_active Expired - Fee Related
- 2007-12-17 EA EA200900838A patent/EA017170B1/ru not_active IP Right Cessation
- 2007-12-17 WO PCT/GB2007/004831 patent/WO2008075012A1/en not_active Ceased
-
2009
- 2009-05-27 IL IL198989A patent/IL198989A0/en unknown
- 2009-05-27 IL IL198990A patent/IL198990A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513438A5 (enExample) | ||
| US7524868B2 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| JP4693787B2 (ja) | Ｃｂ１拮抗活性を有する１，３，５−三置換４，５−ジヒドロ−１ｈ−ピラゾール誘導体 | |
| JP5378988B2 (ja) | ５員環へテロ環誘導体及びその医薬用途 | |
| JP2019031560A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| PT868420E (pt) | Derivados de 3-pirazole-carboxamida tendo afinidade com o receptor dos canabinoides | |
| KR102212981B1 (ko) | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 | |
| JP2009523812A5 (enExample) | ||
| JP2006316054A (ja) | 高コンダクタンス型カルシウム感受性ｋチャネル開口薬 | |
| JP2013533283A (ja) | Ｇｐｒ４０のアゴニスト | |
| JP2006525298A5 (enExample) | ||
| JPH089541B2 (ja) | ピラゾール類を主成分とする脳浮腫抑制剤 | |
| JP2005509038A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| EA017170B1 (ru) | Модуляторы рецептора св1 | |
| EA200970582A1 (ru) | ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH | |
| JP2018529744A5 (enExample) | ||
| JP2009519903A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2010513489A5 (enExample) | ||
| ES2326952B1 (es) | Hidratos de (rac) -n-piperidinil-5-(4-clorofenil)-1-(2,4-diclorofenil)4,5-dihidro-1h-pirazol-3-carboxamida. | |
| CN110372593A (zh) | 大麻素受体拮抗剂/反向激动剂 | |
| ES2326357B1 (es) | Fase amorfa de una pirazolina sustituida, su preparacion y su uso como medicamento. |